Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

NCT02678299 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Aarhus